Clinical Takeaways
- Inflammatory markers (leukotriene B4, TNF-alpha) decline within the first 14 to 28 days of regular administration.
- Extracellular glycosaminoglycan turgor requires 45 to 90 days of continuous nutritional saturation.
- Maximum axonal protection and structural myelin maintenance are locked in between months 3 and 6.
1. Phase 1 (Days 1–14): Downregulating Leukotriene Synthesis
During the initial two weeks of administration, Boswellic acids and Curcuminoids reach steady plasma concentrations, systematically dampening 5-LOX and NF-kB signaling. Biomarker assays document a marked reduction in localized inflammatory cytokines (LTB4, IL-6), corresponding clinically to reduced nocturnal throbbing and fewer sharp sensory spikes.
2. Phase 2 (Days 15–45): Re-Perfusion and Axonal Restabilization
As Bromelain clears microvascular fibrin deposits and Quercetin supports capillary wall elasticity, endoneurial capillary blood flow increases by up to 28% in extremities. Sensory axons receive adequate oxygen and glucose, allowing sodium-potassium pumps to re-establish resting membrane potential and reducing spontaneous ectopic firing.
3. Phase 3 (Days 46–180+): Connective Sheath Remodeling
Connective tissue remodeling follows a slower metabolic cadence than cellular signaling. Between weeks 7 and 24, Glucosamine, Chondroitin, and organic sulfur cofactors (MSM, L-Methionine) incorporate into proteoglycans that build the epineurial sheath, providing durable mechanical protection against micro-compression during daily movement.
Start Your Clinical Protocol Today
Direct domestic warehouse allocations of Nervecept from active batch #2026-B48. 100% money-back guarantee for 60 full days.